Places
Location unknown
Landos has identified novel pathways including NLRX1 and PLXDC2. The NLRX1 pathway works to decrease reactive oxygen species and downregulate effector immune ...
AbbVie to Acquire Landos Biopharma, Further Strengthening ...
news.abbvie.com › 2024-03-25-AbbVie-...
Mar 25, 2024 · Landos' lead asset, NX-13, is a first-in-class, oral NLRX1 agonist in Phase 2 for the treatment of ulcerative colitis (UC).
Headquarters: Virginia
Founded: 2017
People also ask
What does Landos Biopharma do?
Did AbbVie buy Immune drug Developer Landos?
Is AbbVie acquiring autoimmune startup Landos Biopharma?
What company did AbbVie acquire?
Landos Biopharma has a broad inflammation and immunology pipeline of candidates with novel mechanisms.
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases.
In 1915, Salvatore Lando left his home in Ucria, Sicily to travel to America to give his wife and three sons a better life, and arrived in Massachusetts.
Mar 25, 2024 · Abbvie is expanding its pipeline of inflammatory disease drugs, announcing Monday a small deal to acquire biotechnology company Landos Biopharma ...
Our Locations. Acton 297 Main St, Acton MA 978-929-9955. Mon-Thurs. 11AM-9PM Fri-Sat. 11AM-10PM Sun Noon-9PM. Order Online (Acton Only). Clinton
Mar 26, 2024 · AbbVie has entered into a definitive agreement for the acquisition of Landos Biopharma, in a deal totalling $212.5m.
Mar 25, 2024 · Monday's announced buyout of Virginia-based Landos Biopharma adds a mid-stage, oral NLRX1 agonist for ulcerative colitis and Crohn's disease ...